[go: up one dir, main page]

NO20081207L - Isoquinolines as IGF-1R inhibitors - Google Patents

Isoquinolines as IGF-1R inhibitors

Info

Publication number
NO20081207L
NO20081207L NO20081207A NO20081207A NO20081207L NO 20081207 L NO20081207 L NO 20081207L NO 20081207 A NO20081207 A NO 20081207A NO 20081207 A NO20081207 A NO 20081207A NO 20081207 L NO20081207 L NO 20081207L
Authority
NO
Norway
Prior art keywords
igf
isoquinolines
inhibitors
receptor
inhibit
Prior art date
Application number
NO20081207A
Other languages
English (en)
Inventor
Jan Gunzinger
Kurt Leander
Original Assignee
Analytecon Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Analytecon Sa filed Critical Analytecon Sa
Publication of NO20081207L publication Critical patent/NO20081207L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser med formel (I): Forbindelsenes syntetisering er beskrevet. Disse forbindelser er funnet å nedregulere eller inhibere ekspresjonen eller funksjonen av IGF-1-reseptoren.
NO20081207A 2005-09-09 2008-03-07 Isoquinolines as IGF-1R inhibitors NO20081207L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2005002701 2005-09-09
PCT/IB2006/002473 WO2007029106A1 (en) 2005-09-09 2006-09-08 Isoquinolines as igf-1r inhibitors

Publications (1)

Publication Number Publication Date
NO20081207L true NO20081207L (no) 2008-05-27

Family

ID=36350070

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081207A NO20081207L (no) 2005-09-09 2008-03-07 Isoquinolines as IGF-1R inhibitors

Country Status (18)

Country Link
US (1) US8044067B2 (no)
EP (1) EP1931636B1 (no)
JP (1) JP2009507819A (no)
KR (1) KR20080042897A (no)
CN (1) CN101258130B (no)
AT (1) ATE505457T1 (no)
AU (1) AU2006288846B2 (no)
BR (1) BRPI0616732A2 (no)
CA (1) CA2621836C (no)
DE (1) DE602006021327D1 (no)
DK (1) DK1931636T3 (no)
EA (1) EA200800785A1 (no)
ES (1) ES2364673T3 (no)
IL (1) IL189883A (no)
NO (1) NO20081207L (no)
NZ (1) NZ566524A (no)
WO (1) WO2007029106A1 (no)
ZA (1) ZA200801875B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
MX2013008833A (es) 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
EP2699567A1 (en) * 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
ES2723827T3 (es) 2011-11-11 2019-09-02 Univ Duke Terapia de combinación de fármacos para el tratamiento de tumores sólidos
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN104672136B (zh) * 2013-11-30 2017-01-25 沈阳药科大学 1‑取代菲基‑n‑烷基(酰基)‑6,7‑二甲氧基‑1,2,3,4‑四氢异喹啉衍生物及其制备方法和用途
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
WO2020191151A1 (en) * 2019-03-19 2020-09-24 Oncovalent Therapeutics Inc. Sumo inhibitor compounds and uses thereof
CN114456184B (zh) * 2022-02-21 2023-08-22 南华大学附属第一医院 一种3-芳基异喹啉衍生物及其制备与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246805A1 (en) * 1999-11-03 2002-10-09 Albany Molecular Research, Inc. 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
AU2004317166B2 (en) * 2004-03-12 2010-11-11 Analytecon S.A. Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as IGF-1R inhibitors

Also Published As

Publication number Publication date
WO2007029106A1 (en) 2007-03-15
CN101258130A (zh) 2008-09-03
NZ566524A (en) 2011-01-28
US8044067B2 (en) 2011-10-25
IL189883A (en) 2012-07-31
CA2621836C (en) 2013-11-12
ES2364673T3 (es) 2011-09-12
ATE505457T1 (de) 2011-04-15
CN101258130B (zh) 2012-11-28
ZA200801875B (en) 2009-08-26
AU2006288846A1 (en) 2007-03-15
IL189883A0 (en) 2008-11-03
JP2009507819A (ja) 2009-02-26
US20090099229A1 (en) 2009-04-16
DK1931636T3 (da) 2011-07-25
EA200800785A1 (ru) 2008-08-29
KR20080042897A (ko) 2008-05-15
AU2006288846B2 (en) 2011-08-18
CA2621836A1 (en) 2007-03-15
BRPI0616732A2 (pt) 2013-01-01
EP1931636B1 (en) 2011-04-13
HK1115500A1 (en) 2008-11-28
DE602006021327D1 (de) 2011-05-26
EP1931636A1 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
MY152114A (en) Novel pyrazole-4-n-alkoxycarboxamides as microbiocides
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
NO20081207L (no) Isoquinolines as IGF-1R inhibitors
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MX2009005934A (es) Compuestos organicos.
TN2010000101A1 (en) Fungicidal 2-alkylthio-2-quinolinyloxy -acetamide derivatives
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
EA200900676A1 (ru) Ингибиторы вируса гепатита с
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
MX2009010595A (es) Derivados de pirrolopirimidina.
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA201170703A1 (ru) Производные адамантилбензамида
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
NO20081206L (no) Isoquinolines derivatives as IGF -1R inhibitors
WO2008151828A8 (en) Novel microbiocides
UA106880C2 (uk) Нові гербіциди
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
TN2011000355A1 (en) Novel microbiocides
WO2009127718A3 (en) Novel microbiocides
GB0508318D0 (en) Organic compounds
DE602006009789D1 (de) Acetylenderivate
EA200901504A1 (ru) Производные пиразолона, как ингибиторы pde4
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application